An intelligent search tool for clinical trials

Sign In
Back|NCT03435796Recruiting
Official Title

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

Phase
Phase 2/Phase 3
Sponsor
Celgene
Enrollment
1,541
Timeline
Jul 2018 → Nov 2036
About This Study

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

Eligibility Criteria

Inclusion Criteria

  • 1Received at least one gene-modified (GM) T-cell infusion in a previous Celgene sponsored or Celgene alliance partner-sponsored trial, and have discontinued, or completed the post-treatment follow-up period in the parent treatment protocol, as applicable.
  • 2Must understand and voluntarily sign an Informed Consent Form/Informed Assent Form prior to any study-related assessments/procedures being conducted.

Exclusion Criteria

  • 1Not Applicable

Locations

182 sites participating in this study

Winship Cancer Institute of Emory University

Atlanta, Georgia 30322

Recruiting

Sagar Lonial, Site 01103

University of Alabama Birmingham

Birmingham, Alabama 10016

Recruiting

Luciano Costa, Site 01171

Banner MD Anderson Cancer Center

Gilbert, Arizona 85234

Recruiting

Rajneesh Nath, Site 01049

Data sourced from ClinicalTrials.govView on ClinicalTrials.gov →